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Introduction 
La distribution de doxorubicine libre et doxorubicine liposomale pegylée (LiporubicinTM) a été 
comparée après administration intraveineuse ou application via perfusion isolée du poumon (ILP) dans 
le parenchyme pulmonaire et dans la tumeur des poumons de rongeurs, porteurs d'une tumeur 
sarcomateuse. 
Matériel et méthode 
Une tumeur sarcomateuse unique a été générée dans le poumon gauche de 36 rongeurs (Fisher rats) 
suivie, 10 jours plus tard, par application de doxorubicine ou Liporubicin TM soit par perfusion isolée 
du poumon (n = 20) ou administration intraveineuse (n = 12). Deux différentes concentrations ont été 
utilisées (1 OO µg et 400 µg) à doses équimolaires pour les deux formulations de doxorubicine. La 
concentration des agents cytostatiques ont été mesurées dans la tumeur et le parenchyme pulmonaire à 
l'aide de chromatographie (HPLC). 
Résultats 
Les résultats indiquent que pour doxorubicine libre, le taux de concentration dans la tumeur et le 
parenchyme pulmonaire est 3 fois (dosage de 1 OO µg) et 10 fois (dosage de 400 µg) plus élevé après 
ILP par rapport à l'administration intraveineuse. En revanche, pour Liporubicin TM, le taux de 
concentration est similaire dans la tumeur et le parenchyme pulmonaire entre ILP et administration 
intraveineuse, pour les deux doses appliquées. 
Conclusion 
Pour ILP et administration intraveineuse, le ratio entre accumulation de l'agent cytostatique dans la 
tumeur versus dans le parenchyme pulmonaire a été comparé pour les deux formulations de 
doxorubicine ainsi que pour les deux dosages. Pour les deux formulations et dosages de doxorubicine, 
ILP aboutit à un ratio plus élevé par rapport à l'administration intraveineuse. Cependant, pour les deux 
foimulations et dosages de doxorubicine, ILP résulte également en une distribution de l'agent 
cytostatique plus hétérogène dans le parenchyme pulmonaire comparé à l'administration intraveineuse. 
En résumé, l'application de doxorubicine par ILP aboutit donc à une accumulation tumorale élevée et 
à une augmentation du ratio tumeur-parenchyme pulmonaire, mais en même temps également à une 
distribution plus hétérogène dans le parenchyme pulmonaire par rapport à l'application intraveineuse. 
Ceci a été observé pour les deux formulations de doxornbicine et pour les deux dosages appliqué. 
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Abstract 
The distribution of free and liposomal doxorubicin (Liporubicin™) administered by intravenous injection (IV) or isolated lung perfusion 
(ILP) was compared in normal and tumor tissues of sarcoma bearing rodent lungs. A single sarcomatous tumor was generated in the left 
lung of 35 Fischer rats, followed 10 days later by left-sided ILP (n=20) or IV drug administration (n=12), using 100 µg and 400 µg free or 
liposomal doxorubicin, respectively. The tumor and lung tissue drug concentration was measured by HPLC. Free doxorubicin administered 
by ILP resulted in a three-fold (1 OO µg) and 10-fold (400 µg) increase of the drug concentration in the tumor and normal lung tissue 
compared to IV administration. ln contrast, ILP with Liporubicin™ resulted in a similar drug uptake in the tumor and lung tissue compared 
to IV injection. For bath drug formulations and dosages, ILP resulted in a higher tumor to lung tissue drug ratio but also in a higher spatial 
heterogeneity of drug distribution within the lung compared to IV administration. ILP resulted in a higher tumor to lung tissue drug ratio 
and in a more heterogeneous drug distribution within the lung compared to IV drug administration. 
© 2009 Published by European Association for Cardio-Thoracic Surgery. All rights reserved. 
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1. Introduction 
lsolated lung perfusion (ILP) has been recognized as an 
attractive treatment concept against lung metastases since 
it specifically delivers a cytostatic agent to the target 
organ white sparing the systemic circulation. Doxorubicin-
based ILP was shown to cause a high drug uptake in the 
lungs with minimal leakage in the systemic circulation and 
toxicity [ 1-5]. However, we previously observed that the 
penetration of doxorubicin or Liporubicin™ - a pegylated 
liposomal encapsulated formulation of doxorubicin -
administered by ILP was significantly lower in sarcomas 
grown in rodent lungs compared to normal lung parenchyma 
[6]. We have also recently shown that doxorubicin-based 
ILP can lead to a heterogeneous drug distribution within the 
perfused lung and a high variability in drug distribution 
between animais [7, 8]. This could, in part, explain the 
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inconsistent results obtained in patients undergoing ILP for 
lung metastases, irrespective of the cytostatic agent and 
drug dose used. 
Here, we hypothesized that the concentration, formula-
tion and administration of doxorubicin affects its distribu-
tion in normal and tumor tissues and could help optimize 
the tumor to lung tissue drug ratio. Using our previously 
described sarcoma mode!, we compared the tumor /normal 
parenchyma drug uptake following IV or ILP administration 
of doxorubicin and Liporubicin™. For each condition, we 
determined the drug uptake in tumors and lung parenchyma 
by HPLC, the tumor/lung ratio and the drug distribution 
variability in different lung compartments. 
2. Material and methods 
Male Fischer rats (Charles River, France) weighing 250-
300 g were used. They were treated in accordance with 
the Animal Welfare Act, the National lnstitute of Health 
'Guidelines for the Care and Use of Laboratory Animais' 
and according to the Local Ethical Committee of the 
University of Lausanne. 
Thirty-five Fischer rats underwent tumor implantation in 
their left lung using a syngeneic methylcholanthrene-
induced sarcoma (MCA) cell line [9] followed 10 days later 
by isolated lung perfusion (ILP, n = 20) or intravenous 
administration (IV, n = 12) of free or liposomal encapsulated 
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doxorubicin (Liporubicin™) as previously described [6, 9]. 
ILP and IV drug administration were performed for both 
drug formulations at equimolar drug doses of 1 OO µ,g and 
400 µ,g, respectively. Sixty minutes following ILP and 
70 min following IV injection, the animals were sacrificed 
and the lungs were harvested. Drug concentrations in the 
tumor and the normal surrounding lung were assessed by 
high performance liquid chromatography (HPLC) as previ-
ously described [6, 7, 10, 11]. ln addition, the concentra-
tions of doxorubicin in tissues were separately determined 
in the upper, middle and lower part of each perfused lung 
to assess the coefficient of variation (CV%) as previously 
described [6]. Three untreated animals served as controls 
for histological and immunohistochemical analysis. 
Doxorubicin concentrations in tumors and normal lung 
parenchyma were compared for both doxorubicin formula-
tions using a Student's t-test for unrelated samples. Varia-
bilities in doxorubicin lung tissue levels were expressed as 
the coefficients -of variation of tissue concentration in the 
three parts of perfused lungs for both doxorubicin formu-
lations and drug doses and were compared using the 
Student's t-test. A bidirectional hypothesis was applied 
and significance accepted at P<0.05. 
3. Results 
3. 1. Contrais 
Histological assessment of untreated tumors revealed a 
well-circumscribed sarcomatous tumor in each lung, mainly 
formed by large undifferentiated cells. lmmunostaining for 
von Willebrand factor revealed an extensive vascular net-
work composed of small vessels and capillaries and present 
throughout the tumors as previously described [6]. Spon-
taneous necrosis was observed in < 2% of the tumor volume 
for each case analyzed. Tumor growth within the pleural 
cavity was not identified in any of the animals. 
3.2. Drug concentrations in tumor and Lung tissue 
(Tables 1 and 2) 
Free doxorubicin administered by ILP resulted in a three-
(100 µ,g) to 10-fold (400 µ,mg) increase of drug concentra-
tion in the tumor (P=0.048) and in the lung (P=0.0002) 
compared to IV drug administration. However, doxorubicin 
concentrations in tumors were always lower than in lung 
Table 1 
Tissue concentration, ratio of tumor to normal tissue drug concentration and 
coefficient of variation (CV%) of free and liposomal encapsulated doxorubicin 
after isolated lung perfusion (mean values±S.D.) 
Doxorubicin Liporubicin™ 
100 µ,g 400 µ,g 100 µ,g 400 µ,g 
Tissue concentration (µ,g/g) 
Lung 13.8±4.3 58.5±20.1 2.0±0.7 5.2±3.7 
Tumor 3.9±2.5 36.9±10.4 0.8±0.5 3.2±3.5 
Ratio 0.27±0.1 0.67±0.2 0.53±0.5 0.54±0.2 
CV%* 27% 24% 49% 28% 
*CV%, coefficient of variation of doxorubicin levels measured in the upper, 
middle, and lower tumor-free part of the perfused lung. 
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Table 2 
Tissue concentration, ratio of tumor to normal tissue drug concentration and 
coefficient of variation (CV%) of free and liposomal encapsulated doxorubicin 
after IV drug application (mean values±S.D.) 
Doxorubicin Liporubicin™ 
1 OO µ,g 400 µ,g 1 OO µ,g 400 µ,g 
Tissue concentration (µ,g/g) 
Lung 3.7 ±0.2 10.8±0.8 1.8±0.6 8.2±0.2 
Tumor 1.5±0.2 2.9±0.8 0.5±0.02 3.4±0.2 
Ratio 0.39±0.04 0.27±0.1 0.28±0.1 0.41 ±0.04 
CV%' 13% 5% 12% 11% 
'CV%, coefficient of variation of doxorubicin levels measured in the upper, 
middle, and lower tumor-free part of the perfused lung. 
tissue in all animals, for bath drug doses and modes of drug 
administration assessed. 
ln contrast, Liporubicin™ resulted for each drug dose in 
similar drug concentrations in the tumor and normal lung 
tissues following ILP or IV administration. lnterestingly, the 
increase of Liporubicin™ drug dose did not affect tumor or 
normal tissue drug concentration following ILP but signifi-
cantly increased these parameters following IV application. 
Liporubicin™ concentrations in tumors were always lower 
than in the normal lung tissue, for bath drug doses and 
bath modes of drug administration assessed. 
3.3. Ratio of tumor ta Lung tissue drug concentration 
(Fig. 1) 
To determine how the doxorubicin administration, for-
mulation or dose affected its penetration in tumors, we 
determined the tumor to normal tissue drug ratio for each 
of the previous experiments. Free doxorubicin: increasing 
the drug dose during ILP significantly improved the tumor 
to lung tissue drug ratio (P=0.003). This holds not true for 
IV application of free doxorubicin. Comparing IV application 
with ILP, the ratio was significantly higher for ILP at a drug 
dose of 400 µ,g (P=0.02) but not at a dose of 100 µ,g. 
Liporubicin™: ILP revealed for bath drug doses a higher 
tumor to lung tissue drug ratio than IV application although 
the differences were not significant. After ILP, bath drug 
doses resulted in a similar ratio; after IV administration, 
the ratio was higher with the higher drug dose but not 
statistically significant (P= 0.06). 
1 
0.9 
0.8 
0.7 
0.6 
0.5 
0.4 
0.3 
0.2 
9.1 
0 
lllllLP 
DIV 
Fig. 1. Ratio of tumor to lung tissue drug concentration in sarcoma bearing 
lungs for ILP and IV drug administration of 100 µ,g and 400 µ,g doxorubicin 
and equimolar-dosed Liporubicin™. 
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J.4. Spatial drug distribution after ILP and IV 
drug administration 
ILP led to a wide inter-animal variability and a hetero-
geneous spatial drug distribution within the perfused lung 
for both doxorubicin formulations at both drug doses as 
demonstrated by the large coefficients of variation (CV%) 
(Table 1 ). Both, inter-animal variability and spatial drug 
distribution was less pronounced after IV drug application, 
for both drug formulations (Table 2). 
4. Discussion 
Since advanced sarcoma often presents with lung meta-
stases without extra thoracic tumor manifestation, doxo-
rubicin-based ILP has been assessed under clinicat and 
experimental conditions as an alternative method for the 
delivery of high-dose chemotherapy while minimizing 
systemic toxicity. Although effective drug delivery to the 
perfused lung was obtained, ILP has failed to demonstrate 
effective tumor control in clinicat trials [1-3]. We have 
previously shown that ILP with doxorubicin results in an 
uneven distribution of drug within the perfused lung [6-8] 
and that little doxorubicin penetrates tumors in a rodent 
model of sarcoma metastasis to the lung [6, 7]. Fluores-
cence microscopie assessment revealed that doxorubicin 
fails to cross the endothelial barrier of vessels within the 
tumors during ILP in this model [7]. 
Here, we compared the drug uptake in tumors and normal 
lung parenchyma, the tumor to normal lung tissue drug 
ratio and the pattern of drug distribution in the lung after 
ILP and IV drug administration of doxorubicin and equimolar 
dosed Liporubicin™ in a rat model of sarcoma metastasis 
to the lungs. Histological assessment and immunostaining 
for von Willebrand's factor showed that untreated sarco-
matous tumors were well-circumscribed, had a rich vascular 
network consisting of fine branching capillaries witnessing 
the presence of a well developed tumor vascularization 
and did not present spontaneous necrosis. 
Doxorubicin administered by ILP resulted in a three-
( 100 µg) to 10-fold ( 400 µg) increase in drug concentration 
in the lung and tumor tissues compared to IV administra-
tion. However, both modes of doxorubicin administration 
resulted in a consistently lower drug uptake in tumors than 
in normal lung tissue, for both drug doses applied. The 
highest tumor to lung tissue drug ratio was obtained with 
400 µg of doxorubicin administered by ILP, however, the 
spatial distribution of doxorubicin in the lung parenchyma 
after ILP was highly variable within animais and between 
animais as previously reported in rodent [7] and porcine [8] 
models. 
We then conducted the same experiments using a pegy-
lated liposomal encapsulated form of doxorubicin 
(Liporubicin™). Liposomal delivery systems for anthracyc-
lines have shown several advantages for intravenous appli-
cation compared with the administration of the free drug. 
They have been shown to improve drug delivery to tumors 
while decreasing toxicity to normal tissues [12-14]. The 
tumor-targeting mechanism relies on the size of liposomes, 
which render them difficult to extravasate through the 
capillaries of normal tissues outside of the reticulo-endo-
thelial system. 
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ln our study, we found that Liporubicin™-based ILP result-
ed for both drug doses in a similar tumor and lung tissue 
drug uptake compared to IV application which may be 
explained by the specific pharmacokinetic profile of liposo-
mal doxorubicin [12-14]. However, ILP with Liporubicin™ 
revealed a consistently lower drug uptake in tumors and 
lung tissue compared to equimolar-dosed doxorubicin. This 
could be due to the microvascular properties of the sarco-
ma model used in this study. lndeed, previous work in 
various tumor types has shown that the convective forces 
involved in drug distribution can be limited by the high 
intratumoral interstitial fluid pressure. ln this situation, 
the major driving force becomes diffusion which is mostly 
affected by the drug molar mass. Here, while the size of 
Liporubicin™ may increase its specificity for the tumor 
vasculature compared to doxorubicin, it may also limit its 
distribution because of the increase in size and molar mass. 
Finally, another element that could limit the distribution 
of Liporubicin™ administered by ILP is the absence of 
enzymes that have the capacity to de-pegylate 
Liporubicin™ and liberate doxorubicin in the lung perfusion 
solute. 
Conversely, Liporubicin™-based ILP revealed for both drug 
doses a higher tumor to lung tissue drug ratio than IV 
application although the differences were not significant 
due to the great inter-animal variability after ILP. ln addi-
tion, the tumor to lung tissue drug ratio was not signifi-
cantly different between doxorubicin and Liporubicin™-
based ILP. These findings suggest that Liporubicin™ may 
have advantages for drug escalating ILP schedules since an 
increase of the drug dose may allow an enhanced tumor 
drug uptake without exposing the lung parenchyma to 
excessive doxorubicin concentrations and to a risk of doxo-
rubicin-induced lung toxicity. 
Finally, similarly to doxorubicin, Liporubicin™ adminis-
tered by ILP was associated with a higher heterogeneity of 
doxorubicin distribution and inter-animal variability com-
pared to IV application implicating that this phenomenon 
is related to the mode of drug delivery and cannot be 
alleviated by liposomal encapsulation of doxorubicin. 
ln conclusion, ILP administration of both doxorubicin for-
mulations resulted in a trend for better tumor to lung tissue 
drug ratio than IV administration with a significant increase 
in this ratio. for free doxorubicin at a dose of 400 µg. 
Although Liporubicin™ administered by ILP did not cause a 
higher tumor to lung tissue drug ratio compared to IV, its 
lung concentrations were significantly lower than that of 
doxorubicin. The latter could thus bear an advantage 
for investigational ILP protocols with drug-escalating 
schedules. 
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